Difluoro analogue of UCS15A triggers activation of exogenously expressed c-Src in HCT 116 human colorectal carcinoma cells

References

• Pawson T, Nash P. Assembly of cell regulatory systems through protein interaction domains. Science 2003; 300: 445–452
   PubMed Web of Science ®Google Scholar
• Seet BT, Dikic I, Zhou MM, Pawson T. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006; 7: 473–483
   PubMed Web of Science ®Google Scholar
• Gmeiner WH, Horita DA. Implications of SH3 domain structure and dynamics for protein regulation and drug design. Cell Biochem Biophys 2001; 35: 127–140
   PubMed Web of Science ®Google Scholar
• Mayer BJ. SH3 domains: Complexity in moderation. J Cell Sci 2001; 114: 1253–1263
   PubMed Web of Science ®Google Scholar
• Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918–7927
   PubMed Web of Science ®Google Scholar
• Roskoski R, Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004; 324: 1155–1164
   PubMed Web of Science ®Google Scholar
• Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114–130
   PubMed Web of Science ®Google Scholar
• Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12: 1398–1401
   PubMed Web of Science ®Google Scholar
• Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695–701
   PubMed Web of Science ®Google Scholar
• Missbach M, Jeschke M, Feyen J, Muller K, Glatt M, Green J, Susa M. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437–449
   PubMed Web of Science ®Google Scholar
• Neckers L, Mimnaugh E, Schulte TW. Hsp90 as an anti-cancer target. Drug Resist Updat 1999; 2: 165–172
   PubMedGoogle Scholar
• Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 260–266
   PubMed Web of Science ®Google Scholar
• Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998; 16: 2639–2645
   PubMed Web of Science ®Google Scholar
• Violette SM, Shakespeare WC, Bartlett C, Guan W, Smith JA, Rickles RJ, Bohacek RS, Holt DA, Baron R, Sawyer TK. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption. Chem Biol 2000; 7: 225–235
   PubMed Web of Science ®Google Scholar
• Sharma SV, Oneyama C, Yamashita Y, Nakano H, Sugawara K, Hamada M, Kosaka N, Tamaoki T. UCS15A, a non-kinase inhibitor of Src signal transduction. Oncogene 2001; 20: 2068–2079
   PubMed Web of Science ®Google Scholar
• Oneyama C, Nakano H, Sharma SV. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 2002; 21: 2037–2050
   PubMed Web of Science ®Google Scholar
• Oneyama C, Agatsuma T, Kanda Y, Nakano H, Sharma SV, Nakano S, Narazaki F, Tatsuta K. Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: Potent analogs of UCS15A. Chem Biol 2003; 10: 443–451
   PubMed Web of Science ®Google Scholar
• Welman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD, Dive C. Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia 2006; 8: 905–916
   PubMedGoogle Scholar
• Welman A, Cawthorne C, Barraclough J, Smith N, Griffiths GJ, Cowen RL, Williams JC, Stratford IJ, Dive C. Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression. J Cell Biochem 2005; 94: 1148–1162
   PubMedGoogle Scholar
• Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005; 13: 861–871
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727–748
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery, Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA. Gaussian, Inc., Walling Ford, CT 2004, Gaussian 03 Revision C.02, Frisch
   Google Scholar
• Vedejs E, Chapman RW, Fields SC, Lin S, Schrimpf MR. Conversion of arylboronic acids into potassium aryltrifluoroborates: Convenient precursors of arylboron difluoride lewis acids. J Org Chem 1995; 60: 3020–3027
   Web of Science ®Google Scholar
• Johnstone RAW, Rose ME. A rapid, simple, and mild procedure for alkylation of phenols, alcohols, amides and acids. Tetrahedron 1979; 35: 2169–2173
   Web of Science ®Google Scholar
• Wenkert E, Goodwin TE. 4-Formyl-2-cyclohexenone derivatives. Synth Comm 1977; 7: 409–415
   Web of Science ®Google Scholar